Vectura Group PLC (LON:VEC) insider Andrew Derodra acquired 135 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were acquired at an average cost of GBX 111 ($1.44) per share, for a total transaction of £149.85 ($194.53).
Andrew Derodra also recently made the following trade(s):
- On Tuesday, June 6th, Andrew Derodra acquired 135 shares of Vectura Group PLC stock. The shares were acquired at an average cost of GBX 111 ($1.44) per share, for a total transaction of £149.85 ($194.53).
Vectura Group PLC (LON:VEC) opened at 112.90 on Friday. The company’s market capitalization is GBX 765.07 million. The company has a 50-day moving average price of GBX 112.71 and a 200 day moving average price of GBX 131.11. Vectura Group PLC has a 12 month low of GBX 109.50 and a 12 month high of GBX 166.97.
COPYRIGHT VIOLATION WARNING: “Andrew Derodra Acquires 135 Shares of Vectura Group PLC (VEC) Stock” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/18/vectura-group-plc-vec-insider-acquires-149-85-in-stock-updated.html.
Several brokerages have commented on VEC. Shore Capital reiterated a “buy” rating on shares of Vectura Group PLC in a report on Wednesday. N+1 Singer reiterated a “hold” rating on shares of Vectura Group PLC in a report on Thursday, June 29th. Peel Hunt reiterated a “hold” rating and set a GBX 160 ($2.08) price target on shares of Vectura Group PLC in a report on Wednesday. Numis Securities Ltd restated a “buy” rating and issued a GBX 225 ($2.92) price objective on shares of Vectura Group PLC in a research note on Friday, May 5th. Finally, Royal Bank Of Canada downgraded shares of Vectura Group PLC to an “underperform” rating in a research note on Tuesday, April 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of GBX 210.13 ($2.73).
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
What are top analysts saying about Vectura Group PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vectura Group PLC and related companies.